Partner with us

At Immedica, partnerships are at the heart of everything we do. They are—and will continue to be—a cornerstone of our commercial success and long-term growth.

Since 2018, we have successfully executed 16 acquisitions and licensing or distribution agreements, expanding our portfolio and strengthening our position as a trusted partner in rare diseases. Our team brings a proven track record of successful collaborations with both US biotech and European companies, offering deep expertise, operational flexibility, and experience across diverse alliance structures.

With our commitment to partnership and commercial excellence, we provide biotech innovators with a strong platform to bring rare disease treatments to patients across our markets.
 

Bringing treatments to patients with an unmet medical need is in the very core of our business.

Our current partnerships are key, but we continuously scan the market for new investment opportunities. We have an ongoing dialogue with several companies that possess assets where we believe that we, in the Immedica region, can create value for all relevant stakeholders, starting with the patient. On an annual basis, Immedica conducts a large number of evaluations of new interesting business opportunities.

Bringing treatments to patients with an unmet medical need is in the very core of our business and to be able to deliver on this, partnerships are essential. That is why a significant part of our operations is dedicated to business development and evaluation of potential transactions.